| 跌3091 | 涨2149 | | --- | --- | | 成交额6181亿 | 预测成交额1.92万亿,缩1270亿 | 12月9日开盘，A股市场震荡拉升，创业板指涨逾1%，沪指跌0.03%，深成指涨0.35%。 | 上证指数 | 深证成指 | 北证50 | | --- | --- | --- | | 3922.79 | 13376.53 | 1418.57 | | -1.28 -0.03% | +46.54 +0.35% | -7.68 -0.54% | | 科创50 | 创业板指 | 万得全A | | 1353.91 | 3224.50 | 6322.00 | | +3.12 +0.23% | +34.23 +1.07% | +6.53 +0.10% | | 沪深300 | 中证500 | 中证A500 | | 4624.80 | 7179.66 | 5564.18 | | +3.05 +0.07% | +7.29 +0.10% | +2.81 +0.05% | | 中证1000 | 深证100 | 中证红利 | | 7437.69 | 5895.60 | 5502.05 | | +14.65 ...

Market Overview - Major indices opened lower but quickly rebounded, with the ChiNext Index and the Sci-Tech 50 Index turning positive [1] Sector Performance - CPO concept stocks continued to perform strongly, with Zhongci Electronics hitting the daily limit, and Shaanxi Huada and Dekeli rising over 10% [2] - The innovative drug sector saw gains, with Haichuang Pharmaceutical-U increasing over 14%, and Zhaoyan New Drug, Peking University Pharmaceutical, and Chengdu XianDao rising over 5% [3] - The shipbuilding sector experienced broad gains, with China Shipbuilding and China Power both rising over 3% [4] - Film and cinema stocks were active, with Ciweng Media and Bona Film Group rising over 6%, followed by Huace Film and China Film [5] New Stock Offerings - Yuanchuang Co., Ltd. opened for subscription today, issuing a total of 19.6 million shares at a price of 24.75 yuan, with an earnings per share ratio of 12.93 [6] - The company specializes in the research, production, and sales of rubber track products, holding the top domestic market share according to recent reports [7] Private Placement Announcements - Three companies announced private placement plans, with Purun Co., Ltd. seeing a significant rise of over 17% after resuming trading [8] - Tailong Pharmaceutical plans to issue up to 74.6 million shares at 6.09 yuan each, raising approximately 454 million yuan for working capital and debt repayment [8] Financing Activities - As of December 8, the market's financing balance reached 2.48 trillion yuan, an increase of 186.32 billion yuan from the previous trading day [10] - A total of 49 stocks saw net purchases exceeding 100 million yuan, with Shenghong Technology leading at 1.254 billion yuan [10] - The electronics, non-ferrous metals, and non-bank financial sectors saw significant net purchases, with 18, 5, and 5 stocks respectively [11]

港股创新药概念走强，歌礼制药涨超20%，恒瑞医药、康诺亚、药明生物跟涨。 ...

| 分时 5日 = 5分 15分 30分 60分 图K 周K 月K 年K = | | (x = 其他 · ■ / : 恒生指数 (HSI) | | | | | | --- | --- | --- | --- | --- | --- | --- | | 恒生頻數 但因 · | | 0000 | | 26103.08 103.08 | | | | | -27381.84 | | 呼撞报价 | | | | | | | 27000.0 | 域交量 | 7.46亿 新闻 | 2011133 今天 | 26067.86 | | | | | 成交租 | 196亿 最低 | 26067.04 作者 | 20005.06 | | | | 26500.0 | 其他指数 | | | | | | | | 名称 | | 最新 | 双4 | | | | | 周无脂数 | | 58.92 | -0.08% | | | | | 10.05 | | 47264 0 | +0.22 | | | | 25500.0 | 解解达真 | | 21570.12 | +0.31 | | | | | 标值500 | | 6870,40 | +0.137 | ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 港股速报 | 港股小幅高开 内资券商股全线上扬 12月8日早盘，港股市场小幅高开。 截至发稿，恒生指数报26103.08点，上涨18点，涨幅0.07%。 上周末，证监会主席吴清发表重要致辞，围绕"十五五"时期证券行业的使命责任、一流投资银行与投资机构建设两大核心议题，系统提出9条关键要求。吴 清指出，"十五五"是推进中国式现代化、加快建设金融强国的关键时期，证券行业作为直接融资的主要"服务商"、资本市场的重要"看门人"、社会财富的专 业"管理者"，发展空间广阔、大有可为，必须主动呼应时代召唤，自觉担负四大使命责任。 恒生科技指数报5690.54点，上涨28.08点，涨幅0.50%。 焦点板块方面，受消息面刺激，今日内资券商股全线上扬。 今日早盘表现来看，宏业期货（HK03678）大涨超8%，国泰海通（HK02611）、华泰证券（HK06886）涨超5%，中信证券、招商证券、国联民生涨超4%， 其余内资券商股涨幅在2%~4%区间。ETF方面，香港证券ETF早盘涨超3%。 其他方面，盘面上，科网股涨跌不一，百度涨超4%，美团涨超1%、联想跌 ...

12月8日，港股开盘走势分化，其中恒生指数跌0.07%报26067.86点，恒生科技指数涨0.08%报5666.99 点，国企指数平开报919860点。红筹指数涨0.05%报4262.26点。 盘面上，大型科技股多数走低，腾讯控股跌0.41%，京东集团涨0.26%，小米集团涨0.33%，网易跌 0.09%，美团跌0.66%，快手跌0.65%，哔哩哔哩跌0.49%，百度涨3.29%；九方智投涨9.5%，创新药概念 多数上涨，康方生物涨超2%；中资券商股普遍上涨，华泰证券涨超3%；今日两只新股上市，卓越睿新 涨超23%，纳芯微平开。 世茂集团(00813.HK)：前11个月累计合约销售总额约224.32亿元，同比减少28.03%。 中梁控股(02772)前11个月合约销售额约112.2亿元，同比减少31.75% 时代中国控股(01233.HK)：前11个月累计合同销售金额约为47.87亿元，同比减少43.09%。 正荣地产(06158.HK)：前11个月累计合约销售金额约40.09亿元，同比减少33.07%。 喜相逢集团(02473.HK)：附属与哈啰租车签订业务合作协议 拟于指定城市以"联名店"模式开展汽车租赁 ...

Market Overview - The Hong Kong stock market showed a positive trend with the Hang Seng Index rising by 0.68% to close at 25,935.9 points, while the Hang Seng Tech Index increased by 1.45% to 5,615.43 points [1] - Major technology stocks experienced gains, with Xiaomi Group up by 4.38% and Meituan up by 2.29% [1] - The innovative drug sector led the market, with companies like Genscript Biotech rising over 11% [1] - Semiconductor stocks also performed well, with SMIC and Hua Hong Semiconductor both increasing by over 3% [1] Company News - InnoCare Pharma (02577.HK) announced a strategic cooperation agreement with ON Semiconductor to accelerate the GaN industry ecosystem, potentially generating hundreds of millions in GaN sales in the coming years [2] - Aoyuan Group (03383.HK) reported a pre-sale amount of approximately 8.08 billion yuan for the first 11 months, a decrease of 45.2% year-on-year [3] - Jingrui Holdings (01862.HK) reported a cumulative contract sales amount of approximately 876 million yuan for the first 11 months, down 54.1% year-on-year [4] - China Aluminum International (02068.HK) announced that its subsidiary won a bid for a new electrolytic aluminum project with a total contract value of 3.03 billion yuan [4] - Stone Pharmaceutical Group (01093.HK) received clinical trial approval for a selective 5-HT2A receptor agonist in the U.S. [5] - Fosun Pharma (02196.HK) announced that its subsidiary's FXS887 tablet received clinical trial approval [6] - Zai Lab (02617) and Eucure Biopharma (06996) received regulatory approvals for their respective drugs in China [7] Institutional Insights - Guotai Junan Securities indicated that the short-term adjustment in the Hong Kong market opens up space for a rise in 2026, with over 110 billion yuan of net inflow from southbound funds in November [9] - Huaxia Fund noted that the technology sector in Hong Kong has been oversold due to irrational panic, and the outlook for AI development is pragmatic, suggesting a left-side layout strategy [9] - JPMorgan Chase projected a higher risk of significant increases in the Chinese stock market by 2026, with a 19% upside potential for the MSCI China Index [9] - Invesco expressed optimism about the long-term outlook for Hong Kong and A-shares, highlighting attractive valuations and the influx of mainland tech companies going public in Hong Kong [10]

Core Viewpoint - The innovative pharmaceutical stocks have shown a rebound, with notable increases in share prices for several companies, driven by recent policy developments and market dynamics [1] Group 1: Stock Performance - Gilead Sciences-B (01672) increased by 10.26%, reaching HKD 13.11 [1] - Kangfang Biotech (09926) rose by 4.15%, reaching HKD 123.1 [1] - Zai Lab (09688) saw a 3.36% increase, reaching HKD 15.69 [1] - Xiansheng Pharmaceutical (02096) grew by 2.9%, reaching HKD 13.48 [1] Group 2: Policy Developments - In November, the National Healthcare Security Administration initiated negotiations for the 2025 National Basic Medical Insurance Drug List and the pricing consultation for the commercial insurance innovative drug list [1] - The fourth batch of traditional Chinese medicine centralized procurement was launched, and new policies regarding medical devices were introduced in Beijing [1] - The State Council meeting outlined plans to promote provincial-level coordination of basic medical insurance [1] Group 3: Market Insights - Bohai Securities highlighted the importance of the upcoming release of the new basic medical insurance drug list and the first commercial insurance innovative drug list in early December, indicating potential investment opportunities in related pharmaceutical companies [1] - Zhongyou Securities noted that despite a temporary vacuum in domestic BD outbound transactions, several collaborations with multinational corporations (MNCs) have emerged since Q4, reflecting the recognition of domestic innovative drug companies' R&D capabilities [1] - The strong competitive advantages of China's innovative drug industry, including the capacity of the industry chain, pipeline quantity and quality, and R&D efficiency, are expected to drive long-term industry trends [1]

Market Overview - The Hong Kong stock market showed mixed performance with the Hang Seng Index rising by 0.19% to 25,809.45 points, while the Hang Seng Tech Index increased by 0.58% to 5,567.23 points [1] - Major tech stocks exhibited divergent trends, with Alibaba down 0.26%, Tencent down 0.41%, and JD.com down 0.35%, while Xiaomi rose by 2.88% and Meituan increased by 2.03% [1] - The semiconductor sector saw significant gains, with InnoCare Pharma rising over 4% and the robotics sector led by Sanhua Intelligent Controls surging by 9% [1] Company News - InnoCare Pharma (02577.HK) announced a strategic cooperation agreement with Onsemi to accelerate the GaN industry ecosystem, potentially generating hundreds of millions in GaN sales in the coming years [2] - Agile Group (03383.HK) reported a pre-sale amount of approximately 8.08 billion, a year-on-year decline of 45.2% [3] - Jinke Property (01862.HK) recorded a contract sales amount of about 876 million, down 54.1% year-on-year [4] - Chint New Energy (00182.HK) is collaborating with insurance capital to establish a partnership worth 1.811 billion, aiming to promote renewable energy investments [4] - China Aluminum International (02068.HK) won a contract for a new electrolytic aluminum project valued at 3.03 billion [4] - Stone Pharmaceutical Group (01093.HK) received clinical trial approval for a selective 5-HT2A receptor agonist in the U.S. [5] - Fosun Pharma (02196.HK) obtained clinical trial approval for its subsidiary's FXS887 tablets [6] - Zai Lab (02617) had its Tazemetostat tablets included in the priority review list by the National Medical Products Administration [7] - Diligent Pharma (06996) received approval for its drug in Hong Kong for treating multiple myeloma and diffuse large B-cell lymphoma [7] - Kaisa Group (01813) postponed its liquidation hearing to December 8 [8] Institutional Insights - CCB International noted that internal demand policies are expected to drive market attention towards the upcoming "opening red" expectations, with a potential for a year-end rally in December [9] - Guotai Junan Securities indicated that the recent adjustments in the Hong Kong market may open up space for growth in 2026, with significant net inflows from southbound funds [9] - Everbright Securities highlighted that while there is considerable room for growth compared to previous bull markets, the current market may lack strong catalysts in the short term, leading to a period of consolidation [9]

港股三大指数盘初转跌后快速拉升回暖，恒生科技指数一度涨超1.1%，午间收涨0.58%，恒生指数、国 企指数分别上涨0.19%及0.38%。大型科技股涨跌不一，其中小米涨近3%，百度、腾讯、阿里巴巴飘 绿；据报特朗普政府力推机器人产业发展，机器人概念股爆发，龙头三花智控大涨9%；药品类股集体 拉升回暖，创新药概念股方向涨幅明显，半导体股、内银股多数活跃。另外，餐饮股、濠赌股、纸业股 普跌。(格隆汇) ...